Business
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional opti...
About this update from Appili Therapeutics Inc Class A
[{"type":"text","content":"Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01\n\n\n\n\n Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials\n \n\n\n\n Submitted up to US$97 million in additional U.S. government funding proposals\n \n\n\n HALIFAX, Nova Scotia, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, and its partner Vitalex Biosciences (“Vitalex”) today announced that the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health, has awarded up to US$40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections.\n \n\n The five\n \n -\n \n year contract (number 75N93025C00033) consists of a 22-month base period of performance totalling US$3.6 million, with twelve additional option periods valued at approximately US$36.3 million for a total contract value of approximately US$40 million. Under the terms of the contract, Appili will partner with Vitalex to oversee a comprehensive development program for a Vitalex vaccine, VXV-01 that includes manufacturing, nonclinical studies, clinical and regulatory activities. The NIAID funds are expected to support the development of VXV-01 through Investigational New Drug (“IND”) submission and completion of Phase 1 clinical trials.\n \n\n “VXV-01 has the potential to significantly reduce serious invasive infections caused by\n \n Candida albicans\n \n ,\n \n Candida auris\n \n , and other related healthcare-associated infections,” said Don Cilla, Pharm.D., M.B.A., President and Chief Executive Officer of Appili. “We are excited to bring Appili’s expertise in vaccine development and government contracting to our collaboration with the Vitalex team who have deep knowledge in this field of research to move their promising vaccine candidate forward.”\n \n\n “Vitalex’s second generation VXV-01 vaccine shows impressive protection against lethal in...